-
The recent global outbreak of coronavirus disease-19, also known as COVID-19, has infected more than 142 million people worldwide, causing more than 3 million deaths. It has been shown that up to 40% of hospitalized COVID-19 patients may develop ARDS. Although not proven, anti-inflammatory and anti-cytokine treatments are recommended to suppress the cytokine storm that develops in the early stages of the disease.
In this case report, a case of pulmonary aspergillus developed as a complication of treatment for ARDS caused by covid 19 in a 50-year-old male patient will be presented in the light of current literature.
covid 19 ARDS Pulmuner Aspergilloz Basarılı Weaning Steroid Tedavisi
-
-
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Case Report |
Yazarlar | |
Proje Numarası | - |
Erken Görünüm Tarihi | 18 Mart 2022 |
Yayımlanma Tarihi | 18 Mart 2022 |
Gönderilme Tarihi | 29 Eylül 2021 |
Kabul Tarihi | 5 Ocak 2022 |
Yayımlandığı Sayı | Yıl 2022 Cilt: 39 Sayı: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.